MedicineNephrologyPharmacotherapyAutoimmunityImmunopathologyRheumatologyHypertensive NephropathyImmune-mediated Renal DiseaseNephrotic SyndromeRenal DiseaseRenal Function TestsSystemic Lupus ErythematosusLupus FlareMembranoproliferative Glomerulonephritis TherapyMembranous Nephropathy TherapyNephrotic Syndrome TreatmentPrednisolone UseRenal Dysfunction AssessmentRenal Function EvaluationResidual Renal Function
The aim of this study is to report the long-term outcome of pure membranous lupus nephropathy (MLN) treated with glucocorticoid and azathioprine (AZA). A cohort of patients with SLE who had biopsy-confirmed pure MLN was treated initially with prednisone (0.8-1.0 mg/kg/day) and AZA (targeted to 2 mg/kg/day). Patients were followed for the following outcomes: remission rate at 12 months, renal flares, extra-renal flares and renal function deterioration. The cumulative risks of renal flares and renal function decline were studied by Kaplan-Meier analysis. Thirty-eight patients were studied (31 women; age 35.0 +/- 9.2 years; mean SLE duration 48.5 +/- 59 months; WHO Class Va 45%, Vb 55%). Twenty-two (58%) patients were nephrotic and four (11%) were hypertensive at presentation. All patients were treated with prednisolone (0.85 +/- 0.24 mg/kg/day) and AZA (1.72 +/- 0.43 mg/kg/day). At 12 months, 24 (67%) patients achieved complete response (CR), 8 (22%) had partial response (PR) and 4 (11%) were treatment resistant. After a follow-up of 12 +/- 5.8 years, 19 episodes of renal flares (15 proteinuric and 4 nephritic) occurred in 13 (34%) patients. The cumulative risks of renal flares at 5, 10 and 15 years were 19.4, 32.0 and 36.8%, respectively. Retreatment with an augmented dosage of prednisolone, +/- another immunosuppressive agent, resulted in CR and PR in 15 (79%) and 4 (21%) of these flare episodes, respectively. At last visit, three (8%) patients had doubling of serum creatinine, whereas six (16%) patients had decline of creatinine clearance by >/=30% (none developed end stage renal failure). Seven episodes of thromboembolic complications occurred in five (13%) patients and 11 episodes of infective complications (five major, six minor) were reported in seven (18%) patients. In the absence of co-existing proliferative lesions, MLN runs a relatively benign course with low risk of renal function deterioration. Treatment with high-dose prednisolone and AZA is effective, inexpensive and well-tolerated. Prolonged observation shows that one of three patients develop renal flares, which are often proteinuric and responsive to reinduction therapy.
13
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan, Alan S. Cohen, James F. Fries et al. · Arthritis & Rheumatism · 1982 · 14.6K citations
Sequential Therapies for Proliferative Lupus Nephritis
Gabriel Contreras, Victoriano Pardo, Baudouin Leclercq et al. · New England Journal of Medicine · 2004 · 820 citations
Renal Involvement in Systemic Lupus Erythematosus: A Study of 180 Patients from a Single Center
Thi Du Le Huong, T. Papo, Hélène Beaufils et al. · Medicine · 1999 · 232 citations
Prognostic determinants in lupus nephritis: a long-term clinicopathologic study
JV Donadio, EJ Bergstralh, K E Holley · Lupus · 1995 · 195 citations